Loading...
Loading...
CTCX| Name | Value |
|---|---|
| Revenues | 3,728.8K |
| Cost of Revenue | 1,543.8K |
| Gross Profit | 2,185.0K |
| Operating Expense | 6,596.1K |
| Operating I/L | -5,137.4K |
| Other Income/Expense | -6,327.4K |
| Interest Income | 0.0K |
| Pretax | -11,464.8K |
| Income Tax Expense | 401.4K |
| Net Income/Loss | -11,464.8K |
Carmell Therapeutics Corporation specializes in developing plasma-based bioactive material (PBM) to promote tissue repair and growth following injury, disease, and aging. Its primary product, CT-101, serves as a bone healing accelerant for various applications such as tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler. Additionally, the company offers a tissue healing accelerant for androgenetic alopecia and chronic wound healing. By leveraging its innovative PBM technology, Carmell Therapeutics generates revenue through the sale of its bioactive material products to healthcare providers and institutions.
